Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ligand PharmaceuticalsSTU:LGDN 77 EV-to-OCF is 41.55 as of Sep. 21, 2026, which is 75% above its 10-year median of 23.74. GuruFocus rates STU:LGDN with a GF Score™ of 77/100 and a GF Value™ of €163.27 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,406 Biotechnology companies, Ligand Pharmaceuticals ranks worse than 94.24% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Ligand Pharmaceuticals's Enterprise Value is €4,716.4 Mil.
Ligand Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €113.5 Mil. Therefore, Ligand Pharmaceuticals's EV-to-OCF for today is 41.55.
The historical rank and industry rank for Ligand Pharmaceuticals's EV-to-OCF or its related term are showing as below:
STU:LGDN'
s EV-to-OCF Range Over the Past 10 Years
Min: -26.8 Med: 23.74 Max: 124.25
Current: 41.25
During the past 13 years, the highest EV-to-OCF of Ligand Pharmaceuticals was 124.25. The lowest was -26.80. And the median was 23.74.
STU:LGDN's EV-to-OCF is ranked worse than 94.24% of 1406
companies
in the Biotechnology industry
Industry Median: -3.37
vs STU:LGDN: 41.25
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ligand Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Ligand Pharmaceuticals's share price for today is €246.00.
Ligand Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:LGDN vs CRSP, DFTX, XENE: EV-to-OCF Comparison
For the Biotechnology subindustry, Ligand Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ligand Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's EV-to-OCF falls into.
Ligand Pharmaceuticals's current Enterprise Value is €4,716.4 Mil.
Ligand Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €113.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals (STU:LGDN) has a EV-to-OCF of 41.55 as of Sep. 21, 2026. This is 75% above median its historical median of 23.74. According to the industry distribution chart, Ligand Pharmaceuticals ranks #1325 out of 1406 companies in the Biotechnology industry, placing it in the top 94.2%.
Is Ligand Pharmaceuticals' EV-to-OCF too high?
Ligand Pharmaceuticals' current EV-to-OCF of 41.55 is 75% above median its 10-year median of 23.74. Based on the distribution chart, Ligand Pharmaceuticals ranks #1325 out of 1406 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ligand Pharmaceuticals has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' EV-to-OCF compare to CRSP and DFTX?
According to the Biotechnology industry distribution chart, Ligand Pharmaceuticals ranks #1325 out of 1406 companies for EV-to-OCF. This places Ligand Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Ligand Pharmaceuticals's current EV-to-OCF is 41.55, which is 75% above median its own 10-year median of 23.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (STU:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €163.27, compared to a current price of €246.00 — trading 50.7% above its estimated fair value. The current EV-to-OCF is 41.55, which is 75% above median its 10-year median of 23.74. Ligand Pharmaceuticals' overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Ligand Pharmaceuticals (STU:LGDN), the current EV-to-OCF is 41.55 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ligand Pharmaceuticals (STU:LGDN) Overvalued in 2026?
Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued.
The current stock price of €246.00 is trading 50.7% above its estimated GF Value™ of €163.27.
GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for STU:LGDN:
EV-to-OCF: 41.55 (75% above median its 10-year median of 23.74)
GF Value™: €163.27 vs. price of €246.00 (50.7% above fair value)
No single metric tells the full story. See the STU:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
77GF Score
Get the complete analysis for STU:LGDN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LGDN has been successfully added to your 
